Table 1.

CI (Combination Index) and DRI (Dose Reduction Index) values for the drug combinations at 25%, 50%, and 75% levels of inhibition of 8305C and FB3 cell proliferation. SN-38, active metabolite of irinotecan; SU, sunitinib.

Simultaneous treatment				CI values SN-38 + SU
		25% (SU + SN-38)		50% (SU + SN-38)			75% (SU + SN-38)
8305C		4.467		0.844			0.153
FB3		0.044		0.104			0.270
Sequential treatment				SU → SN-38
8305C		1.073		0.910			0.442
FB3		11.432		1.121			0.266
Reverse treatment				SN-38 → SU
8305C		2.589		1.069			0.442
FB3		11.826		1.236			0.313
		25%		DRI values 50%			75%
Simultaneous treatment				SN-38 + SU
	SU		SN-38	SU	SN-38	SU		SN-38
8305C	0.666		0.318	3.886	1.705	22.69		9.141
FB3	200.36		25.68	601.87	9.76	1808		3.71
Sequential treatment				SU → SN-38
	SU		SN-38	SU	SN-38	SU		SN-38
8305C	1.194		0.571	3.099	1.340	8.038		3.145
FB3	0.094		1.209	1.442	2.339	22.04		4.523
Reverse treatment				SN-38 → SU
	SU		SN-38	SU	SN-38	SU		SN-38
8305C	2.882		1.378	2.515	1.088	2.195		0.859
FB3	0.091		1.168	1.308	2.121	18.76		3.851